Research Abstract
My initial academic and professional experience was in decision analysis and disease modeling, first at Stanford and then at Strategic Decisions Group. In recognition of this expertise, I was elected Fellow of the Society of Decision Professionals. As part of my medical training, I have gained experience in clinical research and health outcomes modeling, including dedicated research training during medical school and residency, and Harvard Catalyst courses in biostatistics and grant writing. I was selected to attend the AACR/ASCO Methods in Clinical Cancer Research workshop, developing a Phase 2 protocol in cholangiocarcinoma. I have been working with MGH’s Institute for Technology Assessment (ITA) since 2015. Mentored by Dr Pari Pandharipande, the Director of the ITA, we have developed a model of MRI screening strategies for first-degree family members of pancreatic ductal adenocarcinoma (PDAC) patients, the basis for my current research into the cost-effectiveness of germline genetic testing in this disease. In March 2020 I was awarded a K08 to support this work. Upon completion of fellowship in June 2017, I joined the faculty at BIDMC in the Medical Oncology division, with a clinical focus in GI Oncology and specifically hepatobiliary and pancreatic malignancies. In early 2020 I was promoted to Assistant Professor and became a senior scientist at the ITA. I am DF/HCC lead PI for 4 clinical trials and Site PI for 12 clinical trials largely in hepatobiliary cancers.